World's Best Scientists 2026 revealed!
George I. Papakostas

George I. Papakostas

D-Index & Metrics

Psychology

D-Index
76
Citations
19614
World Ranking
1726
National Ranking
1018

George I. Papakostas publication distribution in Psychology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Psychology in 2026. The highlighted bar marks where George I. Papakostas sits on this spectrum.

31–40 publications: 6 scientists 41–50 publications: 52 scientists 51–60 publications: 138 scientists 61–70 publications: 299 scientists 71–80 publications: 461 scientists 81–90 publications: 605 scientists 91–100 publications: 713 scientists 101–110 publications: 736 scientists 111–120 publications: 686 scientists 121–130 publications: 670 scientists 131–140 publications: 644 scientists 141–150 publications: 597 scientists 151–160 publications: 576 scientists 161–170 publications: 477 scientists 171–180 publications: 450 scientists 181–190 publications: 397 scientists 191–200 publications: 343 scientists 201–210 publications: 328 scientists 211–220 publications: 313 scientists 221–230 publications: 283 scientists 231–240 publications: 226 scientists 241–250 publications: 196 scientists 251–260 publications: 201 scientists 261–270 publications: 171 scientists 271–280 publications: 151 scientists 281–290 publications: 139 scientists 291–300 publications: 113 scientists 301–310 publications: 102 scientists 311–320 publications: 100 scientists 321–330 publications: 76 scientists 331–340 publications: 92 scientists 341–350 publications: 85 scientists 351–360 publications: 69 scientists 361–370 publications: 71 scientists 371–380 publications: 63 scientists 381–390 publications: 58 scientists 391–400 publications: 57 scientists 401–410 publications: 43 scientists 411–420 publications: 33 scientists 421–430 publications: 50 scientists 431–440 publications: 41 scientists 441–450 publications: 32 scientists 451–460 publications: 27 scientists 461–470 publications: 28 scientists 471–480 publications: 25 scientists 481–490 publications: 28 scientists 491–500 publications: 20 scientists 501–510 publications: 23 scientists 511–520 publications: 26 scientists 521–530 publications: 17 scientists 531–540 publications: 21 scientists 541–550 publications: 14 scientists 551–560 publications: 16 scientists 561–570 publications: 10 scientists 571–580 publications: 22 scientists 581–590 publications: 9 scientists 591–600 publications: 14 scientists 601–610 publications: 9 scientists 611–620 publications: 11 scientists 621–630 publications: 4 scientists 631–640 publications: 7 scientists 641–650 publications: 5 scientists 651–660 publications: 10 scientists 661–670 publications: 8 scientists 671–680 publications: 8 scientists 681–690 publications: 4 scientists 691–700 publications: 3 scientists 701–704 publications: 4 scientists 705+ publications: 100 scientists
31 publications 705+

This scientist: 297 publications — 87th percentile

87% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 705 publications or more.

George I. Papakostas D-index placement in Psychology in 2026

The chart shows the D-index (discipline H-index) distribution of Psychology scientists ranked by Research.com in 2026. The highlighted bar marks where George I. Papakostas sits on this spectrum.

30–31 D-Index: 398 scientists 32–33 D-Index: 702 scientists 34–35 D-Index: 671 scientists 36–37 D-Index: 659 scientists 38–39 D-Index: 641 scientists 40–41 D-Index: 671 scientists 42–43 D-Index: 617 scientists 44–45 D-Index: 558 scientists 46–47 D-Index: 495 scientists 48–49 D-Index: 487 scientists 50–51 D-Index: 445 scientists 52–53 D-Index: 390 scientists 54–55 D-Index: 408 scientists 56–57 D-Index: 345 scientists 58–59 D-Index: 325 scientists 60–61 D-Index: 321 scientists 62–63 D-Index: 248 scientists 64–65 D-Index: 290 scientists 66–67 D-Index: 218 scientists 68–69 D-Index: 219 scientists 70–71 D-Index: 215 scientists 72–73 D-Index: 183 scientists 74–75 D-Index: 169 scientists 76–77 D-Index: 132 scientists 78–79 D-Index: 137 scientists 80–81 D-Index: 120 scientists 82–83 D-Index: 112 scientists 84–85 D-Index: 86 scientists 86–87 D-Index: 101 scientists 88–89 D-Index: 83 scientists 90–91 D-Index: 77 scientists 92–93 D-Index: 70 scientists 94–95 D-Index: 78 scientists 96–97 D-Index: 58 scientists 98–99 D-Index: 53 scientists 100–101 D-Index: 57 scientists 102–103 D-Index: 48 scientists 104–105 D-Index: 53 scientists 106–107 D-Index: 46 scientists 108–109 D-Index: 24 scientists 110–111 D-Index: 35 scientists 112–113 D-Index: 27 scientists 114–115 D-Index: 32 scientists 116–117 D-Index: 31 scientists 118–119 D-Index: 22 scientists 120–121 D-Index: 16 scientists 122–123 D-Index: 24 scientists 124–125 D-Index: 18 scientists 126–127 D-Index: 11 scientists 128–129 D-Index: 19 scientists 130–131 D-Index: 10 scientists 132–133 D-Index: 16 scientists 134–135 D-Index: 10 scientists 136–137 D-Index: 12 scientists 138–139 D-Index: 8 scientists 140–141 D-Index: 5 scientists 142–143 D-Index: 12 scientists 144+ D-Index: 98 scientists
30 D-Index 144+

This scientist: 76 D-Index — 85th percentile

85% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 144 D-Index or more.

Overview

George I. Papakostas is affiliated with Harvard University in the United States and has contributed extensively to research in the fields of Medicine and Neuroscience. Their work often intersects key subfields such as Pharmacology, Biological Psychiatry, Psychiatry and Mental Health, Experimental and Cognitive Psychology, and Cognitive Neuroscience.

The primary focus of Papakostas's research centers on the treatment of major depression, with additional interests spanning tryptophan and brain disorders, mental health research topics, electroconvulsive therapy studies, stress responses and cortisol, functional brain connectivity studies, and bipolar disorder and its treatment.

Their recent papers include:

  • Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation (2021, American Journal of Psychiatry)
  • Efficacy and Safety of Ketamine vs Electroconvulsive Therapy Among Patients With Major Depressive Episode (2022, JAMA Psychiatry)
  • Efficacy of Esketamine Augmentation in Major Depressive Disorder (2020, The Journal of Clinical Psychiatry)
  • International pooled patient-level meta-analysis of ketamine infusion for depression: In search of clinical moderators (2022, Molecular Psychiatry)
  • Impact of Supplementation and Nutritional Interventions on Pathogenic Processes of Mood Disorders: A Review of the Evidence (2021, Nutrients)

Frequent co-authors of Papakostas include:

  • Maurizio Fava (25 publications)
  • Madhukar H. Trivedi (20 publications)
  • Manish K. Jha (15 publications)
  • Marlene P. Freeman (13 publications)
  • Sanjay J. Mathew (11 publications)

They have published predominantly in the following venues:

  • The Journal of Clinical Psychiatry (15 publications)
  • Molecular Psychiatry (3 publications)
  • European Neuropsychopharmacology (3 publications)
  • Journal of Affective Disorders (3 publications)
  • CNS Spectrums (3 publications)

George I. Papakostas's research contributes primarily to understanding and improving treatments for mood disorders, focusing on pharmacological approaches such as ketamine and esketamine treatment for depression. Their work includes meta-analyses and clinical studies aimed at evaluating efficacy, safety, and clinical moderators in treatment outcomes.

Best Publications

  • Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials.

    J. Craig Nelson;George I. Papakostas

  • Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation

    Roger S McIntyre;Roger S McIntyre;Joshua D Rosenblat;Joshua D Rosenblat;Charles B Nemeroff;Gerard Sanacora

  • Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD.

    George I. Papakostas;Maurizio Fava

  • Treatment-resistant depression

    Daniel Souery;George I.George Papakostas;Madhukar Trivedi

  • Quality of life assessments in major depressive disorder: a review of the literature.

    George I. Papakostas;Timothy Petersen;Yasmin Mahal;David Mischoulon

  • Adjunctive Nutraceuticals for Depression: A Systematic Review and Meta-Analyses

    Jerome Sarris;Jenifer Murphy;David Mischoulon;George I. Papakostas

  • Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD)

    Maurizio Fava;Marlene P. Freeman;Martina Flynn;Heidi Judge

  • Are Antidepressant Drugs That Combine Serotonergic and Noradrenergic Mechanisms of Action More Effective Than the Selective Serotonin Reuptake Inhibitors in Treating Major Depressive Disorder? A Meta-analysis of Studies of Newer Agents

    George I. Papakostas;Michael E. Thase;Michael E. Thase;Maurizio Fava;J. Craig Nelson

  • S-Adenosyl Methionine (SAMe) Augmentation of Serotonin Reuptake Inhibitors for Antidepressant Nonresponders With Major Depressive Disorder: A Double-Blind, Randomized Clinical Trial

    George I. Papakostas;David Mischoulon;Irene Shyu;Jonathan E. Alpert

  • A Detailed Examination of Cytokine Abnormalities in Major Depressive Disorder

    N.M. Simon;K. McNamara;C.W. Chow;R.S. Maser

  • Treatment of SSRI-Resistant Depression: A Meta-Analysis Comparing Within- Versus Across-Class Switches

    George I. Papakostas;Maurizio Fava;Michael E. Thase;Michael E. Thase

  • Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis.

    George I. Papakostas;Richard C. Shelton;Juliana Smith;Maurizio Fava

  • L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials.

    George I. Papakostas;Richard C. Shelton;John M. Zajecka;Bijan Etemad

  • Consensus Statement and Research Needs: The Role of Dopamine and Norepinephrine in Depression and Antidepressant Treatment

    David J. Nutt;David S. Baldwin;Anita H. Clayton;Rodney Elgie

  • Efficacy of antidepressants for late-life depression: a meta-analysis and meta-regression of placebo-controlled randomized trials.

    Enrico Tedeschini;Yeciel Levkovitz;Nadia Iovieno;Victoria E. Ameral

  • Relationship between sleep disturbance and depression, anxiety, and functioning in college students.

    Maren Nyer;Amy Farabaugh;B A Kiki Fehling;David Soskin

  • A cross-sectional study of the prevalence of cognitive and physical symptoms during long-term antidepressant treatment

    Maurizio Fava;Lesley M. Graves;Franco Benazzi;Margaret J. Scalia

  • Dopaminergic-based pharmacotherapies for depression

    George I. Papakostas

  • Tolerability of modern antidepressants.

    George I Papakostas

  • Assessment of a multi-assay, serum-based biological diagnostic test for major depressive disorder: a Pilot and Replication Study

    G I Papakostas;R C Shelton;G Kinrys;M E Henry

  • Resolution of sleepiness and fatigue in major depressive disorder: A comparison of bupropion and the selective serotonin reuptake inhibitors.

    George I. Papakostas;David J. Nutt;Lindsay A. Hallett;Vivian L. Tucker

Frequent Co-Authors

Maurizio Fava
Maurizio Fava Harvard University
David Mischoulon
David Mischoulon Harvard University
Jonathan E. Alpert
Jonathan E. Alpert Harvard University
Andrew A. Nierenberg
Andrew A. Nierenberg Harvard University
Richard C. Shelton
Richard C. Shelton University of Alabama at Birmingham
Madhukar H. Trivedi
Madhukar H. Trivedi The University of Texas Southwestern Medical Center
Dan V. Iosifescu
Dan V. Iosifescu New York University
Michael E. Thase
Michael E. Thase University of Pennsylvania
Lee Baer
Lee Baer Harvard University
Jerrold F. Rosenbaum
Jerrold F. Rosenbaum Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring Psychology in the USA often opens doors to related fields such as social work and counseling. Many students discover that a psychology background forms a strong foundation for pursuing advanced roles in mental health and community support.

Depending on your career goals, requirements for becoming a social worker can vary by state. For example, if you want to practice in Oregon, it's essential to understand social worker degree requirements in Oregon, which typically involve earning a bachelor's or master's degree in social work.

Other states have unique pathways as well. In Pennsylvania, aspiring professionals should review the Pennsylvania education requirements for social workers to ensure compliance with local regulations. Similarly, research the degree needed to be a social worker in Rhode Island and the degree needed to be a social worker in South Carolina if you are considering a career in those locations.

Many reputable institutions offer flexible online psychology and social work programs that match these requirements, making it easier for you to start your ideal career path from almost anywhere.

Best Scientists Citing George I. Papakostas

Trending Scientists

Recently Published Articles